North America Hepatitis Delta Virus (HDV) Infection Market – Industry Trends and Forecast to 2031

North America Hepatitis Delta Virus (HDV) Infection Market Analysis and Insights

The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the North America Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.

Data Bridge Market Research analyzes that the North America Hepatitis Delta Virus (HDV) infection market is expected to reach USD 9.49 million by 2031 from USD 6.83 million in 2023, growing at a CAGR of 4.4% in the forecast period of 2024 to 2031.

Market Definition

Hepatitis Delta (HDV) infection is a rare but severe form of viral hepatitis that occurs when the Hepatitis Delta Virus (HDV) infects a liver already infected with Hepatitis B Virus (HBV). HDV is a defective virus that requires HBV to replicate and produce new viral particles, and it is characterized by its ability to rapidly cause liver disease, including acute hepatitis, liver failure, and even death. The coinfection of HBV and HDV leads to a more severe and rapid progression of liver disease compared to HBV infection alone, and it is often associated with higher levels of liver inflammation and fibrosis.

North America Hepatitis Delta Virus (HDV) Infection Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:      

Drivers

• Growing Prevalence of Hepatitis

The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the North America Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.

• Increase in Healthcare Expenditure

The increase in healthcare expenditure has a significant impact on the growth of the North America Hepatitis Delta Virus (HDV) infection market by facilitating more substantial investment in diagnostic technologies and treatment options. As healthcare budgets expand, governments and healthcare organizations are able to allocate more resources towards advanced diagnostic tools for HDV. This investment leads to the development and deployment of more sensitive and accurate testing methods, which enhances early detection rates and drives up demand for diagnostic services. The improved availability of high-quality diagnostic tests contributes directly to market growth by increasing the overall testing and screening activities. Moreover, higher healthcare expenditure often translates into better access to and affordability of treatment options for HDV. As funding increases, there is greater potential for the development and distribution of innovative antiviral therapies and other medical interventions. This expanded access to effective treatments not only improves patient outcomes but also stimulates market growth by creating a more extensive patient base seeking treatment options. Enhanced therapeutic options can lead to better disease management and higher rates of treatment adherence, further boosting demand within the HDV infection market.

Opportunity

• Rising Innovative Drug Development

Pipeline therapies like JNJ-73763989 and Peginterferon Lambda are creating new opportunities for pharmaceutical companies to address the substantial unmet need for effective treatments in this space. JNJ-73763989 is a ground-breaking therapy designed to inhibit the replication of HDV by targeting essential components of the viral life cycle, offering a more precise and potentially effective approach compared to existing treatments. On the other hand, Peginterferon Lambda, a novel form of interferon therapy, is being evaluated for its ability to provide antiviral effects while minimizing the side effects traditionally associated with interferon-based treatments. Its targeted mechanism of action has the potential to improve patient outcomes by offering a more tolerable therapy option.

Restraint/Challenge

• Limited Awareness of Hepatitis Delta Virus (HDV)

Limited awareness of Hepatitis Delta Virus (HDV) infection is a significant restraint for the North America HDV infection market. Many healthcare providers and patients are not aware of the risks and consequences of HDV infection, leading to delayed diagnosis and treatment. This lack of awareness results in patients being diagnosed with liver disease at an advanced stage, making treatment more challenging and increasing the risk of complications and mortality.

• Side Effects of Current Treatments

Pegylated interferon-alpha has been a key therapeutic option for managing HDV due to its ability to induce a sustained viral response. However, its use is hampered by a range of debilitating side effects that can significantly impact patient adherence to the treatment regimen.

Common side effects of pegylated interferon-alpha include flu-like symptoms such as fever, chills, and muscle aches, as well as more severe issues such as fatigue, gastrointestinal disturbances, and psychological effects including depression and anxiety. These side effects can be distressing for patients, often leading to reduced quality of life and difficulty in maintaining consistent treatment. The severity of these adverse effects can discourage patients from completing their prescribed course of therapy, resulting in suboptimal treatment outcomes and potential disease progression.

Recent Developments

• In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry
• In March 2024, Gilead Sciences Inc. completed the acquisition of CymaBay Therapeutics, gaining access to innovative therapies for liver and rare diseases. This acquisition expands Gilead’s research portfolio and strengthens its pipeline, enhancing its capacity to address unmet medical needs. The acquisition of CymaBay provides Gilead with promising new drug candidates and expertise in liver and rare diseases, boosting its research capabilities and expanding its therapeutic offerings
• In March 2024, Gilead Sciences, Inc. and Merus have announced a collaboration to discover novel antibody-based trispecific T-cell engagers, aiming to enhance cancer immunotherapy. This partnership combines Gilead’s expertise with Merus’ innovative technology to develop advanced treatments for cancer
• In March 2024, Alnylam Pharmaceuticals launched the Family Health History Road Trip to promote discussions on hereditary ATTR (hATTR) amyloidosis. Genealogist Bernice Bennett traveled cross-country to highlight the importance of family health history for earlier diagnosis

North America Hepatitis Delta Virus (HDV) Infection Market Scope

The North America Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, drug type, route of administration, age group, gender, transmission, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

• Acute Hepatitis D
•  Chronic Hepatitis D

On the basis of type, the market is segmented into acute hepatitis D, chronic hepatitis D.

Treatment

• Surgery (Liver Transplant)
• Medication

On the basis of treatment, the market is segmented into surgery (liver transplant) and medication.

Drug Type

• Branded
• Generic

On the basis of drug type, the market is segmented into branded and generic.

Route of Administration

• Oral
• Parenteral

On the basis of route of administration, the market is segmented into oral and parenteral.

Age group

• Adults
•  Geriatric
•  Pediatric

On the basis of age group, the market is segmented into adults, geriatric, and pediatric.

Gender

• Female
•  Male

On the basis of gender, the market is segmented into female and male.

Transmission

• Contaminated Needles
•  Exposure to Infected Blood
•  Blood and Plasma Product Transfusion
•  Others

On the basis of transmission, the market is segmented into contaminated needles, exposure to infected blood, blood and plasma product transfusion and others.

End User

• Hospitals
•  Specialty Clinics
•  Home Care Setting
•  Research Institutes and Academic Centers
•  Ambulatory Surgical Centers
•  Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home care setting, research institutes and academic centers, ambulatory surgical centers, and others.

Distribution Channel

• Direct Tender
•  Retail Sales
• Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.

North America Hepatitis Delta Virus (HDV) Infection Market Regional Analysis/Insights

The North America Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, route of administration, dosage form, age group, gender, transmission, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, and Mexico.

U.S. is expected to dominate the Europe Hepatitis Delta (HDV) Infection Market, due to its large immigrant population from countries with high HBV and HDV prevalence, such as China, Southeast Asia, and the Caribbean, who are more likely to carry the virus and require treatment for coinfection.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of large services company and their challenges faced due to large or scarce competition from local and domestic players and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Hepatitis Delta (HDV) Infection Market Share Analysis

The North America Hepatitis Delta (HDV) infection market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in the market are Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc., and Alnylam Pharmaceuticals, Inc. among others.

SKU-72925